Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients
Ingrid Costedoat,Martin Wallaert,Aurelie Gaultier,Robin Vasseur,Clelia Vanhaecke,Manuelle Viguier,Charles Cordelette,Alexandre Denoyer,Marie-Christine Ferrier le Bouëdec,Adrien Coutu,Marie Lamiaux,Thi Ha Châu Tran,Jean Philippe Lacour,Valerie Elmaleh,Florence Tetart,Julie Gueudry,Marie Tauber,Francoise Giordano-Labadie,Myriam Cassagne,Audrey Nosbaum,Coralie Ouilhon,Marie Jachiet,Ramin Tadayoni,Frederic Dezoteux,Delphine Staumont-Salle,Julien Bouleau,Pierre Labalette,Serge Doan,Angele Soria,Bruno Mortemousque,Julien Seneschal,Sebastien Barbarot,FRench Atopic DErmatitis Network from the Groupe de Recherche sur l'Eczema Atopique (GREAT), France
DOI: https://doi.org/10.1111/jdv.18932
Abstract:Background: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective: To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods: A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938-30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635-21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158-13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations: Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion: This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.